Zhengye Biotechnology Holding Ltd (ZYBT) stock
Close on Nov 12, 2026Market cap $71.09MP/E –Yield –
Zhengye Biotechnology Holding Ltd saw revenue fall 37.6% to CN¥116.36M over fiscal 2025. Operating income fell 528.9% to -CN¥70.51M, moving the operating margin from 8.8% to -60.6%. Free cash flow was CN¥12.33M, down 55.1% from a year earlier. At the latest close the market valued the company at CN¥474.58M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- CN¥474.58M
- P/E ratio
- –
- Price to sales
- 4.08
- Price to book
- 1.90
- Dividend yield
- –
- Free cash flow yield
- 2.60%
Fundamentals
- Revenue
- CN¥116.36M
- Net income
- -CN¥69.78M
- Free cash flow
- CN¥12.33M
Trading
- Previous close
- $1.52
- Open
- $1.50
- Day's range
- $1.49 – $1.55
- Volume
- 30,032
- Average volume (20 days)
- 50,129
- RSI (14 days)
- 54.6
- Volatility (1 year)
- 1061.7%
- Relative volume
- 0.01×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ZYBT | S&P 500 | Difference | ZYBT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.2% | -2.7% | −8.5 pts | ||
| 3 months | -3.2% | -1.7% | −1.5 pts | ||
| Year to date | +30.4% | +11.9% | +18.5 pts | ||
| 1 year | -30.6% | +12.0% | −42.5 pts |
Five years at a glance
Fiscal years 2021 to 2025, CNY
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Zhengye Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Zhengye Biotechnology
Pharmaceutical Preparations
Zhengye Biotechnology Holding Limited is an animal healthcare company that develops, manufactures, and sells veterinary biologics. Operating through its operating subsidiaries in China, the company provides veterinary products and health solutions designed for livestock and food-producing animals. Its primary customer base consists of agricultural operators, commercial livestock producers, and farming entities seeking veterinary healthcare products to prevent animal diseases and maintain herd welfare.
Company profile, executives and historyZhengye Biotechnology stock: common questions
What is Zhengye Biotechnology's stock price?
ZYBT closed at $1.50 on Nov 12, 2026, down 1.32% on the day.
What is Zhengye Biotechnology's market cap?
Zhengye Biotechnology was worth $71.09M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
How much revenue does Zhengye Biotechnology make?
Zhengye Biotechnology reported revenue of CN¥116.36M for fiscal 2025, down 37.6% from a year earlier.
Does Zhengye Biotechnology pay a dividend?
No. Zhengye Biotechnology has not paid a cash dividend over the last twelve months.
How has ZYBT stock performed over the past year?
Including dividends, ZYBT returned -30.6% over the past year, against +12.0% for the S&P 500.
Who are Zhengye Biotechnology's competitors?
Companies most similar to Zhengye Biotechnology by business, industry and size include ZOMDF, BGM, PRE, GYRE, KMDA.
See a number that looks wrong?